Microcarriers Market is expected to reach US$ 1,625.84 million by 2030

Cell and Gene Therapy Segment to Hold Significant Share of Microcarriers Market During 2022–2030

According to our latest study on "Microcarriers Market Forecast to 2030 – Global Analysis – Product, Equipment, Application, and End User," the microcarriers market value is expected to reach US$ 1,625.84 million by 2030 from US$ 4,178.86 million in 2022. The report emphasizes the key factors driving the market and prominent players with their developments. The need for cell therapies with a rising incidence of cancer and infectious diseases, and the increasing popularity of outsourcing cell and gene therapy manufacturing boost the key factors driving the microcarriers market growth. However, the high cost of biologics and cell-based therapies hampers the market growth.

Cell therapy is a method used to treat disorders and diseases by changing certain groups of cells or externally providing cells with a particular functionality to cure ailments or restore any body function. Gene therapy uses a gene(s) to prevent, treat, or cure a medical disorder or disease. Gene therapies often work by replacing a defective, an altered, or a missing gene in a patient’s cells with a healthy version of that gene. Microcarriers are becoming a more popular method to scale up cell synthesis for cell therapy applications using bioreactors. As cell treatments are gaining broad acceptance in clinics, companies manufacturing cells for cell and gene therapies continuously focus on making their processes more robust and cost-efficient, further ensuring a streamlined scale-up and effective regulatory compliance. The growth of the cell therapy segment is attributed to the increasing number of products introduced in the market; the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases; and a large number of ongoing clinical trials. In September 2022, Carroucell developed a disruptive technological platform that offers unique flat-shaped microcarriers with a glass xenofree composition for cell culture in bioreactors. Unlike existing technologies, the combination of these novel microcarriers combined with the flexibility of the production process enables a faster, more optimized scale-up of the phases of clinical studies. Further, more than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications.

Based on end user, the microcarriers market is divided into pharmaceutical and biotechnology companies, contract research organizations and contract manufacturing organizations, and academic and research institutes. The pharmaceutical and biotechnology companies segment holds largest market share in 2022. Moreover, the same is estimated to register the highest CAGR of 12.9% in the market during 2022–2030. Pharmaceutical companies hold a major share of the total medicine production. Pharmaceutical manufacturing processes are often based on biotechnology principles that involve the use of bacteria to produce insulin, human growth hormone, and other products. The pharmaceutical and biotechnological industries have witnessed extensive growth in the past decade mainly due to increased R&D activities and regulatory approvals for the introduction of new microbial products. Such a massive scale of innovation is projected to drive the adoption of bioreactors in pharmaceutical and biotechnological manufacturing in the coming years, eventually favoring the microcarriers market growth for the pharmaceutical and biotechnological segment.

Teijin Ltd, Bio-Rad Laboratories Inc, denovoMATRIX GmbH, Sartorius AG, Danaher Corp, Corning Inc, Eppendorf SE, Percell Biolytica AB, Asahi Kasei Corp, and Polysciences Inc are among the leading companies functioning in the microcarriers market.

The report segments the microcarriers market as follows:

Based on product, the microcarriers market is segmented into microcarrier beads, and media and reagents. In 2022, the microcarrier beads segment held a larger market share, and same is estimated to register a higher CAGR during 2022–2030. The microcarriers market, by equipment, is segmented into bioreactors, culture vessels, and others. In 2022, the bioreactors segment held the largest market share, and it is further estimated to register the fastest CAGR during 2022–2030. By application, the microcarriers market is segmented into biopharmaceutical production, cell and gene therapy, tissue engineering and regenerative medicine, and others. In 2022, the biopharmaceutical production segment held the largest market share, and it is further estimated to register the fastest CAGR during 2022–2030. In terms of end user, the microcarriers market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs) and contract manufacturing organizations (CMOs), and academic and research institutes. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022. The same is expected to register the highest CAGR during 2022-2023. Based on geography, the microcarriers market is divided into North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com